Case Data
- Diagnosis
- Case Sequence Num
- Case Site Code
- Case Type
- ICDO Version
- ICD-O-3 Conversion Flag
- Topography Code (ICD-O)
- Histology (Histologic Type ICD-O-3)
- Behavior Code
- Histology (ICD-O-2)
- Behavior Code (ICD-O-2)
- Tumor Grade
- Lymphovascular Invasion
- Class of Case
- Place of Diagnosis
- Date of First Contact
- Date of Diagnosis
- Age at Diagnosis
- Laterality
- Suspense Flag
- Suspense Comment
- Personal
- Hospital Chart No
- Family History
- Marital Status at Diagnosis
- Menopausal Status
- Primary Payer at Diagnosis
- ACOS Sequence Num
- SEER Sequence Num
- Address at Diag 1
- Address at Diag 2
- City at Diag
- State at Diag
- Zip Code at Diag
- Country at Diag
- County at Diag
- Registry Accession Year
- Path Report No
- Tobacco Use Smoking Status
- Diag Confirmation Code
- Collab Stg (Retired after 2017)
- Collaborative Staging
- Regional Lymph Nodes Positive (Collaborative Stage)
- Mets at DX - Bone
- Mets at DX - Brain
- Mets at DX - Liver
- Mets at DX - Distant LN
- Mets at DX - Lung
- Mets at DX - Other
- Summary Stage 1977
- SummStg1977Disp
- Summary Stage 2000
- SummStg2000Disp
- CS Version Input Current
- CS Version Derived
- CS Version Input Original
- SEER Extent Of Disease
- SSDI/Grade
- Grade Clinical
- Grade Pathological
- Grade Post Therapy Clin (yc)
- Grade Post Therapy Path (yp)
- SSDI
- SEER SSF 1 (HPV Status)
- Macroscopic Evaluation of the Mesorectum
- Method of Detection - Breast
- Additional Stage-related Data Items
- Schema List (Auto-Generated)
- Adnexa Uterine Other
- Adrenal Gland
- Ampulla of Vater
- Anus (8th 2018-2022)
- Anus (V9 2023+)
- Appendix (8th 2018-2022)
- Appendix (V9 2023+)
- Grade Clinical (Appendix (V9 2023+))
- Grade Pathological (Appendix (V9 2023+))
- Grade Post Therapy Clin (yc) (Appendix (V9 2023+))
- Grade Post Therapy Path (yp) (Appendix (V9 2023+))
- CEA PreTX Lab Value (Appendix (V9 2023+))
- CEA PreTX Interpretation (Appendix (V9 2023+))
- Histologic Subtype (Appendix (V9 2023+))
- Bile Duct Distal
- Bile Ducts Intrahepatic
- Grade Clinical (Bile Ducts Intrahepatic)
- Grade Pathological (Bile Ducts Intrahepatic)
- Grade Post Therapy Clin (yc) (Bile Ducts Intrahepatic)
- Grade Post Therapy Path (yp) (Bile Ducts Intrahepatic)
- Fibrosis Score (Bile Ducts Intrahepatic)
- Primary Scleros Cholangitis (Bile Ducts Intrahepatic)
- Tumor Growth Pattern (Bile Ducts Intrahepatic)
- Bile Ducts Perihilar
- Biliary Other
- Bladder
- Bone Appendicular Skeleton, Trunk, Skull, and Facial Bones
- Bone Pelvis
- Bone Spine
- Brain (8th 2018-2022)
- Grade Clinical (Brain (8th 2018-2022))
- Grade Pathological (Brain (8th 2018-2022))
- Grade Post Therapy Clin (yc) (Brain (8th 2018-2022))
- Grade Post Therapy Path (yp) (Brain (8th 2018-2022))
- Brain Molecular Markers (Brain (8th 2018-2022))
- Chromosome 1p Status (Brain (8th 2018-2022))
- Chromosome 19q Status (Brain (8th 2018-2022))
- MGMT (Brain (8th 2018-2022))
- Brain (V9 2023+)
- Grade Clinical (Brain (V9 2023+))
- Grade Pathological (Brain (V9 2023+))
- Grade Post Therapy Clin (yc) (Brain (V9 2023+))
- Grade Post Therapy Path (yp) (Brain (V9 2023+))
- Brain Molecular Markers (Brain (V9 2023+))
- Chromosome 1p Status (Brain (V9 2023+))
- Chromosome 19q Status (Brain (V9 2023+))
- MGMT (Brain (V9 2023+))
- Brain Primary Tumor Location (Brain (V9 2023+))
- Breast
- Grade Clinical (Breast)
- Grade Pathological (Breast)
- Grade Post Therapy Clin (yc) (Breast)
- Grade Post Therapy Path (yp) (Breast)
- Lymph Nodes Positive Axillary Level I-II (Breast)
- ER Summary (Breast)
- ER Percent Positive (Breast)
- PR Summary (Breast)
- PR Percent Positive (Breast)
- HER2 Overall Summary (Breast)
- Ki-67 (MIB-1) (Breast)
- Oncotype DX Recur Score - Invasive (Breast)
- Oncotype DX Recur Score - DCIS (Breast)
- Multigene Signature Method (Breast)
- Multigene Signature Result (Breast)
- Response Neoadjuv Therapy (Breast)
- Residual Cancer Burden (RCB) (Breast)
- RCB Class (Breast)
- Oncotype Dx Risk Level - Invasive (Breast)
- Oncotype Dx Risk Level - DCIS (Breast)
- ER Allred Score (Breast)
- PR Allred Score (Breast)
- HER2 IHC Summary (Breast)
- HER2 ISH Summary (Breast)
- HER2 ISH DP Ratio (Breast)
- HER2 ISH DP Copy No (Breast)
- HER2 ISH SP Copy No (Breast)
- Buccal Mucosa
- Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck
- Schema Discriminator 1 (Cervical Lymph Nodes and Unknown Primary)
- Grade Clinical (Cervical Lymph Nodes and Unknown Primary)
- Grade Pathological (Cervical Lymph Nodes and Unknown Primary)
- Grade Post Therapy Clin (yc) (Cervical Lymph Nodes and Unknown Primary)
- Grade Post Therapy Path (yp) (Cervical Lymph Nodes and Unknown Primary)
- Extranodal Exten H&N Clin (Cervical Lymph Nodes and Unknown Primary)
- Extranodal Exten H&N Path (Cervical Lymph Nodes and Unknown Primary)
- LN Size (Cervical Lymph Nodes and Unknown Primary)
- Lymph Nodes H&N Lev I-III (Cervical Lymph Nodes and Unknown Primary)
- Lymph Nodes H&N Lev IV-V (Cervical Lymph Nodes and Unknown Primary)
- Lymph Nodes H&N Lev VI-VII (Cervical Lymph Nodes and Unknown Primary)
- Lymph Nodes H&N Other (Cervical Lymph Nodes and Unknown Primary)
- Cervix Uteri (8th 2018-2020)
- Grade Clinical (Cervix (8th 2018-2020))
- Grade Pathological (Cervix (8th 2018-2020))
- Grade Post Therapy Clin (yc) (Cervix (8th 2018-2020))
- Grade Post Therapy Path (yp) (Cervix (8th 2018-2020))
- FIGO Stage (Cervix (8th 2018-2020))
- LN Status Para-aortic (Cervix (8th 2018-2020))
- Lymph Nodes Assessment Method Para-aortic (Cervix (8th 2018-2020))
- LN Status Pelvic (Cervix (8th 2018-2020))
- Lymph Nodes Assessment Method Pelvic (Cervix (8th 2018-2020))
- Lymph Nodes Distant Mediastinal, Scalene (Cervix (8th 2018-2020))
- Lymph Nodes Distant Assessment Method (Cervix (8th 2018-2020))
- Cervix Uteri (V9 2021+)
- Grade Clinical (Cervix (V9 2021+))
- Grade Pathological (Cervix (V9 2021+))
- Grade Post Therapy Clin (yc) (Cervix (V9 2021+))
- Grade Post Therapy Path (yp) (Cervix (V9 2021+))
- FIGO Stage (Cervix (V9 2021+))
- p16 (Cervix (V9 2021+))
- LN Status Para-aortic (Cervix (V9 2021+))
- Lymph Nodes Assessment Method Para-aortic (Cervix (V9 2021+))
- LN Status Pelvic (Cervix (V9 2021+))
- Lymph Nodes Assessment Method Pelvic (Cervix (V9 2021+))
- Lymph Nodes Distant Mediastinal, Scalene (Cervix (V9 2021+))
- Lymph Nodes Distant Assessment Method (Cervix (V9 2021+))
- Cervix Uteri Sarcoma
- Grade Clinical (Cervix Sarcoma)
- Grade Pathological (Cervix Sarcoma)
- Grade Post Therapy Clin (yc) (Cervix Sarcoma)
- Grade Post Therapy Path (yp) (Cervix Sarcoma)
- FIGO Stage (Cervix Sarcoma)
- Number of Positive Pelvic Nodes (Cervix Sarcoma)
- Number of Examined Pelvic Nodes (Cervix Sarcoma)
- Number of Positive Para-aortic Nodes (Cervix Sarcoma)
- Number of Examined Para-aortic Nodes (Cervix Sarcoma)
- Peritoneal Cytology (Cervix Sarcoma)
- CNS Other (8th 2018-2022)
- Grade Clinical (CNS Other (8th 2018-2022))
- Grade Pathological (CNS Other (8th 2018-2022))
- Grade Post Therapy Clin (yc) (CNS Other (8th 2018-2022))
- Grade Post Therapy Path (yp) (CNS Other (8th 2018-2022))
- Brain Molecular Markers (CNS Other (8th 2018-2022))
- Chromosome 1p Status (CNS Other (8th 2018-2022))
- Chromosome 19q Status (CNS Other (8th 2018-2022))
- MGMT (CNS Other (8th 2018-2022))
- CNS Other (V9 2023+)
- Grade Clinical (CNS Other (V9 2023+))
- Grade Pathological (CNS Other (V9 2023+))
- Grade Post Therapy Clin (yc) (CNS Other (V9 2023+))
- Grade Post Therapy Path (yp) (CNS Other (V9 2023+))
- Brain Molecular Markers (CNS Other (V9 2023+))
- Chromosome 1p Status (CNS Other (V9 2023+))
- Chromosome 19q Status (CNS Other (V9 2023+))
- MGMT (CNS Other (V9 2023+))
- Colon and Rectum
- Grade Clinical (Colon and Rectum)
- Grade Pathological (Colon and Rectum)
- Grade Post Therapy Clin (yc) (Colon and Rectum)
- Grade Post Therapy Path (yp) (Colon and Rectum)
- CEA PreTX Lab Value (Colon and Rectum)
- CEA PreTX Interpretation (Colon and Rectum)
- Tumor Deposits (Colon and Rectum)
- Perineural Invasion (Colon and Rectum)
- Circumferential Resection Margin (Colon and Rectum)
- KRAS (Colon and Rectum)
- Microsatellite Instability (MSI) (Colon and Rectum)
- BRAF Mutational Analysis (Colon and Rectum)
- NRAS Mutational Analysis (Colon and Rectum)
- Conjunctiva
- Corpus Uteri Adenosarcoma
- Grade Clinical (Corpus Adenosarcoma)
- Grade Pathological (Corpus Adenosarcoma)
- Grade Post Therapy Clin (yc) (Corpus Adenosarcoma)
- Grade Post Therapy Path (yp) (Corpus Adenosarcoma)
- FIGO Stage (Corpus Adenosarcoma)
- Number of Positive Pelvic Nodes (Corpus Adenosarcoma)
- Number of Examined Pelvic Nodes (Corpus Adenosarcoma)
- Number of Positive Para-Aortic Nodes (Corpus Adenosarcoma)
- Number of Examined Para-Aortic Nodes (Corpus Adenosarcoma)
- Peritoneal Cytology (Corpus Adenosarcoma)
- Corpus Uteri Carcinoma and Carcinosarcoma
- Grade Clinical (Corpus Carcinoma and Carcinosarcoma)
- Grade Pathological (Corpus Carcinoma and Carcinosarcoma)
- Grade Post Therapy Clin (yc) (Corpus Carcinoma and Carcinosarcoma)
- Grade Post Therapy Path (yp) (Corpus Carcinoma and Carcinosarcoma)
- FIGO Stage (Corpus Carcinoma and Carcinosarcoma)
- Number of Positive Pelvic Nodes (Corpus Carcinoma and Carcinosarcoma)
- Number of Examined Pelvic Nodes (Corpus Carcinoma and Carcinosarcoma)
- Number of Positive Para-aortic Nodes (Corpus Carcinoma and Carcinosarcoma)
- Number of Examined Para-aortic Nodes (Corpus Carcinoma and Carcinosarcoma)
- Peritoneal Cytology (Corpus Carcinoma and Carcinosarcoma)
- Microsatellite Instability (MSI) (Corpus Carcinoma and Carcinosarcoma)
- Corpus Uteri Sarcoma
- Grade Clinical (Corpus Sarcoma)
- Grade Pathological (Corpus Sarcoma)
- Grade Post Therapy Clin (yc) (Corpus Sarcoma)
- Grade Post Therapy Path (yp) (Corpus Sarcoma)
- FIGO Stage (Corpus Sarcoma)
- Number of Positive Pelvic Nodes (Corpus Sarcoma)
- Number of Examined Pelvic Nodes (Corpus Sarcoma)
- Number of Positive Para-aortic Nodes (Corpus Sarcoma)
- Number of Examined Para-aortic Nodes (Corpus Sarcoma)
- Peritoneal Cytology (Corpus Sarcoma)
- Cutaneous Carcinoma of Head and Neck
- Grade Clinical (Cutaneous Carcinoma of Head and Neck)
- Grade Pathological (Cutaneous Carcinoma of Head and Neck)
- Grade Post Therapy Clin (yc) (Cutaneous Carcinoma of Head and Neck)
- Grade Post Therapy Path (yp) (Cutaneous Carcinoma of Head and Neck)
- Perineural Invasion (Cutaneous Carcinoma of Head and Neck)
- LN Size (Cutaneous Carcinoma of Head and Neck)
- High Risk Features (Cutaneous Carcinoma of Head and Neck)
- Cystic Duct
- Digestive Other
- Endocrine Other
- Esophagus (including GE junction) (excluding Squamous)
- Schema Discriminator 1 (Esophagus (including GE junction) (excluding Squamous))
- Schema Discriminator 2 (Esophagus (including GE junction) (excluding Squamous))
- Grade Clinical (Esophagus (including GE junction) (excluding Squamous))
- Grade Pathological (Esophagus (including GE junction) (excluding Squamous))
- Grade Post Therapy Clin (yc) (Esophagus (including GE junction) (excluding Squamous))
- Grade Post Therapy Path (yp) (Esophagus (including GE junction) (excluding Squamous))
- HER2 Overall Summary (Esophagus (including GE junction) (excluding Squamous))
- Esophagus (including GE junction) Squamous
- Schema Discriminator 1 (Esophagus (including GE junction) Squamous)
- Schema Discriminator 2 (Esophagus (including GE junction) Squamous)
- Grade Clinical (Esophagus (including GE junction) Squamous)
- Grade Pathological (Esophagus (including GE junction) Squamous)
- Grade Post Therapy Clin (yc) (Esophagus (including GE junction) Squamous)
- Grade Post Therapy Path (yp) (Esophagus (including GE junction) Squamous)
- Esoph Tumor Epicenter (Esophagus (including GE junction) Squamous)
- HER2 Overall Summary (Esophagus (including GE junction) Squamous)
- Eye Other
- Fallopian Tube
- Floor of Mouth
- Gallbladder
- Genital Female Other
- Genital Male Other
- GIST
- Gum
- Heart, Mediastinum and Pleura
- HemeRetic
- Hypopharynx
- Ill-Defined Other
- Intracranial Gland (8th 2018-2022)
- Intracranial Gland (V9 2023+)
- Kaposi Sarcoma
- Kidney Parenchyma
- Grade Clinical (Kidney Parenchyma)
- Grade Pathological (Kidney Parenchyma)
- Grade Post Therapy Clin (yc) (Kidney Parenchyma)
- Grade Post Therapy Path (yp) (Kidney Parenchyma)
- Invasion Beyond Capsule (Kidney Parenchyma)
- Ipsilateral Adrenal Gland Involvement (Kidney Parenchyma)
- Major Vein Involvement (Kidney Parenchyma)
- Sarcomatoid Features (Kidney Parenchyma)
- Kidney Renal Pelvis
- Lacrimal Gland
- Lacrimal Sac
- Larynx Glottic
- Larynx Other
- Larynx Subglottic
- Larynx Supraglottic
- Lip
- Liver
- Grade Clinical (Liver)
- Grade Pathological (Liver)
- Grade Post Therapy Clin (yc) (Liver)
- Grade Post Therapy Path (yp) (Liver)
- AFP PreTX Lab Value (Liver)
- AFP PreTX Interpretation (Liver)
- Bilirubin PreTX Lab Value (Liver)
- Bilirubin PreTX Unit (Liver)
- Creatinine PreTX Lab Value (Liver)
- Creatinine PreTX Unit (Liver)
- INR Prothrombin Time (Liver)
- Fibrosis Score (Liver)
- Lung (8th 2018-2024)
- Grade Clinical (Lung (8th 2018-2024))
- Grade Pathological (Lung (8th 2018-2024))
- Grade Post Therapy Clin (yc) (Lung (8th 2018-2024))
- Grade Post Therapy Path (yp) (Lung (8th 2018-2024))
- Separate Tumor Nodules (Lung (8th 2018-2024))
- Visceral and Parietal Pleural Invasion (Lung (8th 2018-2024))
- ALK Rearrangement (Lung (8th 2018-2024))
- EGFR Mutational Analysis (Lung (8th 2018-2024))
- Lung (V9 2025+)
- Grade Clinical (Lung (V9 2025+))
- Grade Pathological (Lung (V9 2025+))
- Grade Post Therapy Clin (yc) (Lung (V9 2025+))
- Grade Post Therapy Path (yp) (Lung (V9 2025+))
- Separate Tumor Nodules (Lung (V9 2025+))
- Visceral and Parietal Pleural Invasion (Lung (V9 2025+))
- ALK Rearrangement (Lung (V9 2025+))
- EGFR Mutational Analysis (Lung (V9 2025+))
- PD-L1 (Lung (V9 2025+))
- Lung STAS (Lung (V9 2025+))
- Lymphoma
- Lymphoma-CLL/SLL
- Grade Clinical (Lymphoma-CLL/SLL)
- Grade Pathological (Lymphoma-CLL/SLL)
- Grade Post Therapy Clin (yc) (Lymphoma-CLL/SLL)
- Grade Post Therapy Path (yp) (Lymphoma-CLL/SLL)
- B Symptoms (Lymphoma-CLL/SLL)
- HIV Status (Lymphoma-CLL/SLL)
- NCCN International Prognostic Index (IPI) (Lymphoma-CLL/SLL)
- Lymphocytosis (Lymphoma-CLL/SLL)
- Adenopathy (Lymphoma-CLL/SLL)
- Organomegaly (Lymphoma-CLL/SLL)
- Anemia (Lymphoma-CLL/SLL)
- Thrombocytopenia (Lymphoma-CLL/SLL)
- PTLD (Lymphoma-CLL/SLL)
- Lymphoma Ocular Adnexa
- Major Salivary Glands (8th 2018-2025)
- Grade Clinical (Major Salivary Glands (8th 2018-2025))
- Grade Pathological (Major Salivary Glands (8th 2018-2025))
- Grade Post Therapy Clin (yc) (Major Salivary Glands (8th 2018-2025))
- Grade Post Therapy Path (yp) (Major Salivary Glands (8th 2018-2025))
- Extranodal Exten H&N Clin (Major Salivary Glands (8th 2018-2025))
- Extranodal Exten H&N Path (Major Salivary Glands (8th 2018-2025))
- LN Size (Major Salivary Glands (8th 2018-2025))
- Major Salivary Glands (V9 2026+)
- Grade Clinical (Major Salivary Glands (V9 2026+))
- Grade Pathological (Major Salivary Glands (V9 2026+))
- Grade Post Therapy Clin (yc) (Major Salivary Glands (V9 2026+))
- Grade Post Therapy Path (yp) (Major Salivary Glands (V9 2026+))
- Extranodal Exten H&N Clin (Major Salivary Glands (V9 2026+))
- Extranodal Exten H&N Path (Major Salivary Glands (V9 2026+))
- LN Size (Major Salivary Glands (V9 2026+))
- Maxillary Sinus
- Medulloblastoma (V9 2023+)
- Melanoma Choroid and Ciliary Body
- Schema Discriminator 1 (Melanoma Choroid and Ciliary Body)
- Grade Clinical (Melanoma Choroid and Ciliary Body)
- Grade Pathological (Melanoma Choroid and Ciliary Body)
- Grade Post Therapy Clin (yc) (Melanoma Choroid and Ciliary Body)
- Grade Post Therapy Path (yp) (Melanoma Choroid and Ciliary Body)
- Measured Thickness (Melanoma Choroid and Ciliary Body)
- Measured Basal Diameter (Melanoma Choroid and Ciliary Body)
- Extravascular Matrix Patterns (Melanoma Choroid and Ciliary Body)
- Microvascular Density (MVD) (Melanoma Choroid and Ciliary Body)
- Mitotic Count Uveal Mel (Melanoma Choroid and Ciliary Body)
- Chromosome 3 Status (Melanoma Choroid and Ciliary Body)
- Chromosome 8q Status (Melanoma Choroid and Ciliary Body)
- Melanoma Conjunctiva
- Malignant Melanoma of Head and Neck
- Grade Clinical (Melanoma Head and Neck)
- Grade Pathological (Melanoma Head and Neck)
- Grade Post Therapy Clin (yc) (Melanoma Head and Neck)
- Grade Post Therapy Path (yp) (Melanoma Head and Neck)
- Extranodal Exten H&N Clin (Melanoma Head and Neck)
- Extranodal Exten H&N Path (Melanoma Head and Neck)
- LN Size (Melanoma Head and Neck)
- Lymph Nodes H&N Lev I-III (Melanoma Head and Neck)
- Lymph Nodes H&N Lev IV-V (Melanoma Head and Neck)
- Lymph Nodes H&N Lev VI-VII (Melanoma Head and Neck)
- Lymph Nodes H&N Other (Melanoma Head and Neck)
- Malignant Melanoma of Iris (excluding Ciliary Body)
- Schema Discriminator 1 (Melanoma Iris)
- Grade Clinical (Melanoma Iris)
- Grade Pathological (Melanoma Iris)
- Grade Post Therapy Clin (yc) (Melanoma Iris)
- Grade Post Therapy Path (yp) (Melanoma Iris)
- Measured Thickness (Melanoma Iris)
- Measured Basal Diameter (Melanoma Iris)
- Extravascular Matrix Patterns (Melanoma Iris)
- Microvascular Density (MVD) (Melanoma Iris)
- Mitotic Count Uveal Mel (Melanoma Iris)
- Chromosome 3 Status (Melanoma Iris)
- Chromosome 8q Status (Melanoma Iris)
- Melanoma Skin
- Grade Clinical (Melanoma Skin)
- Grade Pathological (Melanoma Skin)
- Grade Post Therapy Clin (yc) (Melanoma Skin)
- Grade Post Therapy Path (yp) (Melanoma Skin)
- Breslow Thickness (Melanoma Skin)
- Ulceration (Melanoma Skin)
- Mitotic Rate Melanoma (Melanoma Skin)
- LDH Lab Value (Melanoma Skin)
- LDH Upper Limits of Normal (Melanoma Skin)
- LDH Level (Melanoma Skin)
- Clinical Margin Width (Melanoma Skin)
- Merkel Cell Skin
- Grade Clinical (Merkel Cell Skin)
- Grade Pathological (Merkel Cell Skin)
- Grade Post Therapy Clin (yc) (Merkel Cell Skin)
- Grade Post Therapy Path (yp) (Merkel Cell Skin)
- Lymph Nodes Isolated Tumor Cells (Merkel Cell Skin)
- Profound Immune Suppression (Merkel Cell Skin)
- Extranodal Extension Clinical (Merkel Cell Skin)
- Extranodal Extension Pathological (Merkel Cell Skin)
- Middle Ear
- Mouth Other
- Mycosis Fungoides
- Nasal Cavity and Ethmoid Sinus
- Grade Clinical (Nasal Cavity and Ethmoid Sinus)
- Grade Pathological (Nasal Cavity and Ethmoid Sinus)
- Grade Post Therapy Clin (yc) (Nasal Cavity and Ethmoid Sinus)
- Grade Post Therapy Path (yp) (Nasal Cavity and Ethmoid Sinus)
- Extranodal Exten H&N Clin (Nasal Cavity and Ethmoid Sinus)
- Extranodal Exten H&N Path (Nasal Cavity and Ethmoid Sinus)
- LN Size (Nasal Cavity and Ethmoid Sinus)
- Nasopharynx (8th 2018-2024)
- Schema Discriminator 1 (Nasopharynx (8th 2018-2024))
- Grade Clinical (Nasopharynx (8th 2018-2024))
- Grade Pathological (Nasopharynx (8th 2018-2024))
- Grade Post Therapy Clin (yc) (Nasopharynx (8th 2018-2024))
- Grade Post Therapy Path (yp) (Nasopharynx (8th 2018-2024))
- Extranodal Exten H&N Clin (Nasopharynx (8th 2018-2024))
- Extranodal Exten H&N Path (Nasopharynx (8th 2018-2024))
- LN Size (Nasopharynx (8th 2018-2024))
- Nasopharynx (V9 2025+)
- Grade Clinical (Nasopharynx (V9 2025+))
- Grade Pathological (Nasopharynx (V9 2025+))
- Grade Post Therapy Clin (yc) (Nasopharynx (V9 2025+))
- Grade Post Therapy Path (yp) (Nasopharynx (V9 2025+))
- Extranodal Exten H&N Clin (Nasopharynx (V9 2025+))
- Extranodal Exten H&N Path (Nasopharynx (V9 2025+))
- LN Size (Nasopharynx (V9 2025+))
- NET Adrenal Gland
- NET Ampulla of Vater (8th 2018-2023)
- NET Ampulla of Vater (V9 2024+)
- NET Appendix (8th 2018-2023)
- NET Appendix (V9 2024+)
- NET Colon and Rectum (V9 2024+)
- NET Colon and Rectum (8th 2018-2023)
- NET Duodenum (8th 2018-2023)
- NET Duodenum (V9 2024+)
- NET Jejunum and Ileum (V9 2024+)
- NET Jejunum and Ileum (8th 2018-2023)
- Grade Clinical (NET Jejunum and Ileum (8th 2018-2023))
- Grade Pathological (NET Jejunum and Ileum (8th 2018-2023))
- Grade Post Therapy Clin (yc) (NET Jejunum and Ileum (8th 2018-2023))
- Grade Post Therapy Path (yp) (NET Jejunum and Ileum (8th 2018-2023))
- Ki-67 (MIB-1) (NET Jejunum and Ileum (8th 2018-2023))
- NET Pancreas (8th 2018-2023)
- NET Pancreas (V9 2024+)
- NET Stomach (8th 2018-2023)
- NET Stomach (V9 2024+)
- Orbital Sarcoma
- Oropharynx HPV-Associated (V9 2026+)
- Schema Discriminator 2 (Oropharynx HPV-Associated (V9 2026+))
- Grade Clinical (Oropharynx HPV-Associated (V9 2026+))
- Grade Pathological (Oropharynx HPV-Associated (V9 2026+))
- Grade Post Therapy Clin (yc) (Oropharynx HPV-Associated (V9 2026+))
- Grade Post Therapy Path (yp) (Oropharynx HPV-Associated (V9 2026+))
- Extranodal Exten H&N Clin (Oropharynx HPV-Associated (V9 2026+))
- Extranodal Exten H&N Path (Oropharynx HPV-Associated (V9 2026+))
- LN Size (Oropharynx HPV-Associated (V9 2026+))
- Oropharynx HPV-Associated (8th 2018-2025)
- Schema Discriminator 1 (Oropharynx HPV-Associated (8th 2018-2025))
- Schema Discriminator 2 (Oropharynx HPV-Associated (8th 2018-2025))
- Grade Clinical (Oropharynx HPV-Associated (8th 2018-2025))
- Grade Pathological (Oropharynx HPV-Associated (8th 2018-2025))
- Grade Post Therapy Clin (yc) (Oropharynx HPV-Associated (8th 2018-2025))
- Grade Post Therapy Path (yp) (Oropharynx HPV-Associated (8th 2018-2025))
- Extranodal Exten H&N Clin (Oropharynx HPV-Associated (8th 2018-2025))
- Extranodal Exten H&N Path (Oropharynx HPV-Associated (8th 2018-2025))
- LN Size (Oropharynx HPV-Associated (8th 2018-2025))
- Oropharynx HPV-Independent
- Schema Discriminator 1 (Oropharynx HPV-Independent)
- Schema Discriminator 2 (Oropharynx HPV-Independent)
- Grade Clinical (Oropharynx HPV-Independent)
- Grade Pathological (Oropharynx HPV-Independent)
- Grade Post Therapy Clin (yc) (Oropharynx HPV-Independent)
- Grade Post Therapy Path (yp) (Oropharynx HPV-Independent)
- Extranodal Exten H&N Clin (Oropharynx HPV-Independent)
- Extranodal Exten H&N Path (Oropharynx HPV-Independent)
- LN Size (Oropharynx HPV-Independent)
- Ovary
- Palate Hard
- Pancreas
- Parathyroid
- Penis
- Pharynx Other
- Placenta
- Plasma Cell Disorders
- Plasma Cell Myeloma
- Schema Discriminator 1 (Plasma Cell Myeloma)
- Grade Clinical (Plasma Cell Myeloma)
- Grade Pathological (Plasma Cell Myeloma)
- Grade Post Therapy Clin (yc) (Plasma Cell Myeloma)
- Grade Post Therapy Path (yp) (Plasma Cell Myeloma)
- Serum Beta-2 Microglobulin Pretreatment Level (Plasma Cell Myeloma)
- Serum Albumin Pretreatment Level (Plasma Cell Myeloma)
- High Risk Cytogenetics (Plasma Cell Myeloma)
- LDH Level (Plasma Cell Myeloma)
- PTLD (Plasma Cell Myeloma)
- Pleural Mesothelioma (8th 2018-2024)
- Pleural Mesothelioma (V9 2025+)
- Primary Cutaneous Lymphoma (excluding MF and SS)
- Grade Clinical (Primary Cutaneous Lymphoma (excluding MF and SS))
- Grade Pathological (Primary Cutaneous Lymphoma (excluding MF and SS))
- Grade Post Therapy Clin (yc) (Primary Cutaneous Lymphoma (excluding MF and SS))
- Grade Post Therapy Path (yp) (Primary Cutaneous Lymphoma (excluding MF and SS))
- PTLD (Primary Cutaneous Lymphoma (excluding MF and SS))
- Primary Peritoneal Carcinoma
- Grade Clinical (Primary Peritoneal Carcinoma)
- Grade Pathological (Primary Peritoneal Carcinoma)
- Grade Post Therapy Clin (yc) (Primary Peritoneal Carcinoma)
- Grade Post Therapy Path (yp) (Primary Peritoneal Carcinoma)
- FIGO Stage (Primary Peritoneal Carcinoma)
- CA-125 PreTx Interpretation (Primary Peritoneal Carcinoma)
- Residual Tumor Volume Post Cytoreduction (Primary Peritoneal Carcinoma)
- Prostate
- Grade Clinical (Prostate)
- Grade Pathological (Prostate)
- Grade Post Therapy Clin (yc) (Prostate)
- Grade Post Therapy Path (yp) (Prostate)
- PSA Lab Value (Prostate)
- Number of Cores Positive (Prostate)
- Number of Cores Examined (Prostate)
- Gleason Patterns Clinical (Prostate)
- Gleason Score Clinical (Prostate)
- Gleason Patterns Pathological (Prostate)
- Gleason Score Pathological (Prostate)
- Gleason Tertiary Pattern (Prostate)
- Respiratory Other
- Retinoblastoma
- Retroperitoneum
- Sinus Other
- Skin Eyelid
- Skin Other
- Small Intestine
- Soft Tissue Abdomen and Thoracic (excluding Heart, Mediastinum and Pleura)
- Schema Discriminator 2 (Soft Tissue Abdomen and Thoracic)
- Grade Clinical (Soft Tissue Abdomen and Thoracic)
- Grade Pathological (Soft Tissue Abdomen and Thoracic)
- Grade Post Therapy Clin (yc) (Soft Tissue Abdomen and Thoracic)
- Grade Post Therapy Path (yp) (Soft Tissue Abdomen and Thoracic)
- Bone Invasion (Soft Tissue Abdomen and Thoracic)
- Soft Tissue Head and Neck
- Soft Tissue Other
- Soft Tissue Sarcoma - Unusual Histologies and Sites
- Soft Tissue Trunk and Extremities
- Schema Discriminator 2 (Soft Tissue Trunk and Extremities)
- Grade Clinical (Soft Tissue Trunk and Extremities)
- Grade Pathological (Soft Tissue Trunk and Extremities)
- Grade Post Therapy Clin (yc) (Soft Tissue Trunk and Extremities)
- Grade Post Therapy Path (yp) (Soft Tissue Trunk and Extremities)
- Bone Invasion (Soft Tissue Trunk and Extremities)
- Stomach
- Testis
- Grade Clinical (Testis)
- Grade Pathological (Testis)
- Grade Post Therapy Clin (yc) (Testis)
- Grade Post Therapy Path (yp) (Testis)
- S Category Clinical (Testis)
- S Category Pathological (Testis)
- AFP Pre-Orchiectomy Lab Value (Testis)
- AFP Pre-Orchiectomy Range (Testis)
- hCG Pre-Orchiectomy Lab Value (Testis)
- hCG Pre-Orchiectomy Range (Testis)
- LDH Pre-Orchiectomy Range (Testis)
- AFP Post-Orchiectomy Lab Value (Testis)
- AFP Post-Orchiectomy Range (Testis)
- hCG Post-Orchiectomy Lab Value (Testis)
- hCG Post-Orchiectomy Range (Testis)
- LDH Post-Orchiectomy Range (Testis)
- Thymus (8th 2018-2024)
- Thymus (V9 2025+)
- Thyroid
- Thyroid Medullary
- Tongue Anterior
- Trachea
- Urethra
- Urethra-Prostatic
- Urinary Other
- Vagina
- Grade Clinical (Vagina)
- Grade Pathological (Vagina)
- Grade Post Therapy Clin (yc) (Vagina)
- Grade Post Therapy Path (yp) (Vagina)
- FIGO Stage (Vagina)
- LN Status Femoral-Inguinal (Vagina)
- Lymph Nodes Assessment Method Femoral-Inguinal (Vagina)
- LN Status Para-aortic (Vagina)
- Lymph Nodes Assessment Method Para-aortic (Vagina)
- LN Status Pelvic (Vagina)
- Lymph Nodes Assessment Method Pelvic (Vagina)
- Lymph Nodes Distant Mediastinal, Scalene (Vagina)
- Lymph Nodes Distant Assessment Method (Vagina)
- Vulva (8th 2018-2023)
- Grade Clinical (Vulva (8th 2018-2023))
- Grade Pathological (Vulva (8th 2018-2023))
- Grade Post Therapy Clin (yc) (Vulva (8th 2018-2023))
- Grade Post Therapy Path (yp) (Vulva (8th 2018-2023))
- FIGO Stage (Vulva (8th 2018-2023))
- LN Status Femoral-Inguinal (Vulva (8th 2018-2023))
- Lymph Nodes Assessment Method Femoral-Inguinal (Vulva (8th 2018-2023))
- LN Status Pelvic (Vulva (8th 2018-2023))
- Lymph Nodes Assessment Method Pelvic (Vulva (8th 2018-2023))
- Lymph Nodes Laterality (Vulva (8th 2018-2023))
- Vulva (V9 2024+)
- Grade Clinical (Vulva (V9 2024+))
- Grade Pathological (Vulva (V9 2024+))
- Grade Post Therapy Clin (yc) (Vulva (V9 2024+))
- Grade Post Therapy Path (yp) (Vulva (V9 2024+))
- FIGO Stage (Vulva (V9 2024+))
- LN Status Femoral-Inguinal (Vulva (V9 2024+))
- Lymph Nodes Assessment Method Femoral-Inguinal (Vulva (V9 2024+))
- LN Status Pelvic (Vulva (V9 2024+))
- Lymph Nodes Assessment Method Pelvic (Vulva (V9 2024+))
- Lymph Nodes Laterality (Vulva (V9 2024+))
- p16 (Vulva (V9 2024+))
- AJCC Docs
- Directly Coded Summ Stg 2000
- Directly Coded Summary Stage 2018
- AJCC Staging Of Cancer
- Tumor Size Pathologic
- Tumor Size Clinical
- Tumor Size Summary
- AJCC Staging Edition
- cT Classification
- cN Classification
- cM Classification
- cTNM Stage Group
- cTNM Descriptor
- Staged By - Clinical
- pT Classification
- pN Classification
- pM Classification
- pTNM Stage Group
- pTNM Descriptor
- Alt (Ped) Stage Sys
- Alt (Ped) Stage
- Managing Physician
- Primary Surgeon
- Medical Oncologist
- Radiation Oncologist
- Staged By - Pathologic
- AJCC TNM Clinical T
- AJCC TNM Clinical T Suffix
- AJCC TNM Clinical N
- AJCC TNM Clinical N Suffix
- AJCC TNM Clinical M
- AJCC TNM Clinical Stage Group
- AJCC TNM Pathological T
- AJCC TNM Pathological T Suffix
- AJCC TNM Pathological N
- AJCC TNM Pathological N Suffix
- AJCC TNM Pathological M
- AJCC TNM Pathological Stage Group
- AJCC TNM Post Therapy Path (yp) T
- AJCC TNM Post Therapy Path (yp) T Suffix
- AJCC TNM Post Therapy Path (yp) N
- AJCC TNM Post Therapy Path (yp) N Suffix
- AJCC TNM Post Therapy Path (yp) M
- AJCC TNM Post Therapy Path (yp) Stage Group
- AJCC TNM Post Therapy Clin (yc) T
- AJCC TNM Post Therapy Clin (yc) T Suffix
- AJCC TNM Post Therapy Clin (yc) N
- AJCC TNM Post Therapy Clin (yc) N Suffix
- AJCC TNM Post Therapy Clin (yc) M
- AJCC TNM Post Therapy Clin (yc) Stage Group
- Admin NoTx
- ACOS Coding Original
- Type of Reporting Src
- Abstracted By
- ACOS Coding Current
- Reason No Therapy (Non-def Surg)
- Reason No Therapy (Surg)
- Reason No Therapy (Chemo)
- Reason No Therapy (Rad)
- Reason No Therapy (Horm)
- Reason No Therapy (Immuno)
- Reason No Therapy (Trans)
- Reason No Therapy (Other)
- Tx Follow-back Needed
- Systemic Therapy/Surg Seq
- Radiation/Surgery Sequence
- Treatment Status
- Tx Start Date (ACOS)
- Tx Composite (First)
- Tx Composite (All)
- QA Review Status
- Central Review Status
- Date Case Completed CoC
- Neoadjuvant Therapy
- Neoadjuvant Therapy - Clinical Response
- Neoadjuvant Therapy - Treatment Effect
- Date No First Therapy
- ACoS
- Overrides
- Summary Stage Overrides
- Acsn/Class/Seq Override
- HospSeq/DxConf Override
- COC-Site/Type Override
- HospSeq/Site Override
- Site/TNM-StgGrp Override
- Age/Site/Morph Override (IF15)
- SeqNo/DxConf Override (IF23)
- Site/Lat/SeqNo Override (IR09)
- Surg/DxConf Override (IF46)
- Site/Type Override (IF25)
- Histology Override (MORPH)
- Report Source Override (IF04)
- Ill-Define Site Override (IF22)
- Leuk, Lymphoma Override (IF48)
- Site/Behavior Override (IF39)
- Site/Eod/Dx Dt Override (IF40)
- Site/Lat/Eod Override (IF41)
- Site/Lat/Morph Override (IF42)
- CS Override
- Override TNM Tis
- Override TNM Stage
- Override TNM 3
- Historical
- Grade Path Value
- Grade Path System
- Tumor Marker 1
- Tumor Marker 2
- Tumor Marker 3
- Biopsy Procedure
- Multiplicity Counter
- Date Multiple Tumors
- Date Multiple Tumors Flag
- Type of Multiple Tumors
- Ambiguous Terminology
- Date of Conclusive Terminology
- Date of Conclusive Terminology Flag
- SEER Extent
- SEER PEP
- Tumor Size (largest)
- SEER Lymph Node
- Site of Mets
- Occupation Code
- COVID-19 --DX PROC--LAB TESTS
- COVID-19 Impact - SURGERY
- COVID-19 Impact - CHEMO
- COVID-19 Impact - RADIATION (BEAM)
- COVID-19 Impact - RADIATION OTHER
- COVID-19 Impact- HORMONE
- COVID-19 Impact - BMT
- COVID-19 TEXT
- Text
- Case Misc
- Case Other Sequence Num
- Case Other Site Code
- Year of Diagnosis
- Case Other Comment
- Modified By (Case Other)
- Time Modified (Case Other)
- EOD Coding System
- Vendor
- Census Tract 2000
- Census Tract Certainty 2000
- Census Tract 2010
- Census Block Group 2010
- Census Tract Certainty 2010
- Latitude
- Longitude
- GIS Coordinate Quality
- Date Case Completed
- Date Case Last Updated
- Import Reporting Facility
- Area Development District
- Appalachia
- Beale Code 2003
- Beale Code 2013
- Best Stage Group
- SEER Site
- ICCC Site
- ICCC Extended Site
- Source Status
- Class Hospital Id
- Original Case Type
- Patient Acc No
- ArchiveFIN
- Modified By (Case)
- Time Modified (Case)
- Case User Defined Data a
- 2018 Best Stage Group
- Census Tract
- Census Tract Coding System
- CPDMS Create Case From Pathology Report Application